Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US11846642B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2019 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Oct 9, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.